The Singapore company is an innovative biomedical company that designs & develops, manufactures and market a range of unique & patented diagnostic solutions for the early detection of nasopharyngeal, gastric and hepatocellular carcinoma. They are seeking distributors to represent their in-vitro diagnostic kits which are used for the early detection cancer particular in Germany, UK, Netherlands, Italy and Spain.
The company aims to improve healthcare by offering a range of innovative technologies and services through their group of companies. Headquartered in Singapore with a regional presence, the company is making a positive impact on lives around the world. Established in 2007, the Singapore company is a trusted provider of innovation, reliable and clinically-proven diagnostic solutions to the medical and healthcare industry. They are a fully integrated company that generates the full product pipelines from scientific research to in-house developmental work of patented technology. Key products includes immunoassays for early diagnosis and sensitive detection of oncology, infectious, neurodegenerative and other diseases. The company designs & develops, manufactures and market a range of unique & patented diagnostic solutions for the early detection of: - Nasopharyngeal Carcinoma (NPC). The company develops an in-vitro diagnostic intended for qualitative and semi-qualitative detection of IgA antibodies in human serum samples for nasopharyngeal carcinoma. It uses proprietary proteins developed by the company to identify specific IgA antibody to EA seromarker segment. - Gastric Carcinoma (stomach cancer) The company develops an in-vitro diagnostic intended for early detection of gastric carcinoma using a patented biomarker. This biomarker was discovered to be expressed at high levels in the patient’s plasma samples. Additionally, risk factor for gastric cancer like Helicobacter pylori (H. pylori) infection, does not influence the biomarkers expression levels within plasma. The competition between the patented biomarker and its specific antibodies is the gist of how this product functions. Positive or negative results obtained through calculations help to determine the patients’ status of gastric cancer. - Hepatocellular Carcinoma (liver cancer) The company develops an in-vitro diagnostic intended for early detection of hepatocellular carcinoma using a patented biomarker. Elevated levels of this biomarker were identified within hepatocellular carcinoma patients’ plasma. Internal research studies by this company indicated that this patented biomarker produces better sensitivity than Alpha-fetoprotein (AFP) blood test and ultrasound exam (every 6 to 12 months). Their research and production facilities are certified for compliance to EN ISO13485:2016. The company is looking for distributors with existing sales network in the medical and healthcare sector, particular with hospitals and medical clinics via distribution services agreement(s). The company also has plans to expand their market globally.
Innovations and advantages
The company is an integrated healthcare and wellness provider with an established biomedical R&D arm that holds exclusive patents of clinical diagnostics. They also leverage technology to create positive customer experiences. The company adopt a clinical-based approach to generate evidence-based results, and take pride in delivering results characterised by high quality, reliability and precision. They create healthcare solutions that empower individuals to live life to the fullest. The company uses proprietary protein developed by the company to identify specific IgA antibody to EA seromarker for diagnostic of Nasopharyngeal Carcinoma (NPC). The advantage of this product is that it has higher specificity in comparison to other Epstein Barr Virus (EBV) related markers, resulting in fewer false positive during screening. This is particularly important and is a feature that their customers especially value. Fewer false positive results reduce unnecessary worry to patients and the requirement for them to undergo unnecessary procedures or treatments. Other advantages of their other products for liver cancer includes patented biomarker which produces better sensitivity than Alphafetoprotein (AFP) blood test and ultrasound exam which tested every 6 - 12 months.
Market application codes
05001002 In-vitro diagnostics
Intellectual property rights
Type of partner sought
The ideal candidate should have an existing sales network in the medical and healthcare sector, particular with hospitals and medical clinics. The partner is responsible to present a marketing plan on how the distributorship will develop and be promoted in their targeted countries. The distribution would be under the client company's brand.